diphtheria tetanus acellular pertussis vaccines

Summary

Summary: Combined vaccines consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and an acellular form of PERTUSSIS VACCINE. At least five different purified antigens of B. pertussis have been used in various combinations in these vaccines.

Top Publications

  1. ncbi Comparative investigation of the safety of hexavalent vaccines for primary scheduled infant immunizations in Germany over a time period of 2 years
    Gerd M Lackmann
    Outpatient Paediatric Office, Hamburg, Germany
    Med Sci Monit 10:PI96-8. 2004
  2. ncbi Pertussis in adolescents and adults: should we vaccinate?
    Grace M Lee
    Center for Child Health Care Studies, Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care and Harvard Medical School, Boston, Massachusetts 02215, USA
    Pediatrics 115:1675-84. 2005
  3. ncbi The use of combination vaccines has improved timeliness of vaccination in children
    Helen Kalies
    Department of Pediatric Epidemiology, Institute for Social Pediatrics and Adolescent Medicine of Ludwig Maximilians University, Munich, Germany
    Pediatr Infect Dis J 25:507-12. 2006
  4. ncbi Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine
    Michael Zinke
    Tangstedter Landstr, Hamburg, Germany
    Hum Vaccin 5:592-8. 2009
  5. ncbi Clinical relevance of lower Hib response in DTPa-based combination vaccines
    J Poolman
    SmithKline Beecham Biologicals, Rixensart, Belgium
    Vaccine 19:2280-5. 2001
  6. ncbi Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination
    M B Rennels
    University of Maryland School of Medicine, Baltimore, USA
    Pediatr Infect Dis J 19:417-23. 2000
  7. ncbi Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine
    Michael E Pichichero
    University of Rochester Medical Center, Rochester, New York 14642, USA
    J Pediatr 151:43-9, 49.e1-2. 2007
  8. ncbi Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001
    Kristine M Bisgard
    DVM, National Immunization Program, Centers for Disease Control and Prevention, 1600 Clifton Rd, M S E 61, Atlanta, GA 30333
    Pediatrics 116:e285-94. 2005
  9. ncbi A model for immunological correlates of protection
    Andrew J Dunning
    Wyeth Vaccines Research, 401 N Middletown Road, Pearl River, NY 10965, USA
    Stat Med 25:1485-97. 2006
  10. ncbi Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study
    Scott A Halperin
    Department of Pediatrics, Dalhousie University and the IWK Health Centre, Halifax, NS
    Clin Invest Med 25:243-51. 2002

Detail Information

Publications199 found, 100 shown here

  1. ncbi Comparative investigation of the safety of hexavalent vaccines for primary scheduled infant immunizations in Germany over a time period of 2 years
    Gerd M Lackmann
    Outpatient Paediatric Office, Hamburg, Germany
    Med Sci Monit 10:PI96-8. 2004
    ..The aim of this study was to evaluate the safety of hexavalent vaccines over a time period of 2 years...
  2. ncbi Pertussis in adolescents and adults: should we vaccinate?
    Grace M Lee
    Center for Child Health Care Studies, Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care and Harvard Medical School, Boston, Massachusetts 02215, USA
    Pediatrics 115:1675-84. 2005
    ..Combined acellular pertussis vaccines for adolescents and adults are available in Canada, Australia, and Germany and may soon be considered for use in the United States...
  3. ncbi The use of combination vaccines has improved timeliness of vaccination in children
    Helen Kalies
    Department of Pediatric Epidemiology, Institute for Social Pediatrics and Adolescent Medicine of Ludwig Maximilians University, Munich, Germany
    Pediatr Infect Dis J 25:507-12. 2006
    ..We examined whether the use of combination vaccines has improved the timing of these vaccinations...
  4. ncbi Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine
    Michael Zinke
    Tangstedter Landstr, Hamburg, Germany
    Hum Vaccin 5:592-8. 2009
    ..The HBV vaccine challenge dose was well tolerated. These studies show that primary and booster vaccination with combined DTPa-HBV-IPV/Hib (Infanrix hexa) induces sustained immune memory against hepatitis B up to age 9 years...
  5. ncbi Clinical relevance of lower Hib response in DTPa-based combination vaccines
    J Poolman
    SmithKline Beecham Biologicals, Rixensart, Belgium
    Vaccine 19:2280-5. 2001
    ..It is likely therefore that the DTPa-HBV-IPV/Hib combination will be efficacious against Hib disease...
  6. ncbi Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination
    M B Rennels
    University of Maryland School of Medicine, Baltimore, USA
    Pediatr Infect Dis J 19:417-23. 2000
    ..A trial was conducted in which infants received a DTaP and Hib vaccine, separately (+) or combined (/), with either all OPV, all IPV or sequential IPV-OPV for the primary series of vaccinations...
  7. ncbi Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine
    Michael E Pichichero
    University of Rochester Medical Center, Rochester, New York 14642, USA
    J Pediatr 151:43-9, 49.e1-2. 2007
    ....
  8. ncbi Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001
    Kristine M Bisgard
    DVM, National Immunization Program, Centers for Disease Control and Prevention, 1600 Clifton Rd, M S E 61, Atlanta, GA 30333
    Pediatrics 116:e285-94. 2005
    ....
  9. ncbi A model for immunological correlates of protection
    Andrew J Dunning
    Wyeth Vaccines Research, 401 N Middletown Road, Pearl River, NY 10965, USA
    Stat Med 25:1485-97. 2006
    ....
  10. ncbi Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study
    Scott A Halperin
    Department of Pediatrics, Dalhousie University and the IWK Health Centre, Halifax, NS
    Clin Invest Med 25:243-51. 2002
    ..The objective of this study was to measure the safety and immunogenicity of a meningococcal C conjugate vaccine when given with routine childhood vaccines...
  11. pmc Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis
    Caroline Roduit
    World Health Organization Collaborating Center for Vaccinology and Neonatal Immunology, Department of Pathology and Pediatrics, University of Geneva, Geneva, Switzerland
    Infect Immun 70:3521-8. 2002
    ..pertussis challenge. Thus, neonatal priming with antipertussis vaccines should be considered to reduce the window of vulnerability to pertussis at the time of its greatest severity...
  12. ncbi [Time for booster doses against whooping cough for 10-year-old children]
    Rose Marie Carlsson
    Smittskyddsinstitutet, Stockholm
    Lakartidningen 102:2394-8. 2005
    ....
  13. ncbi Hypotonic-hyporesponsive episode in a 7-month-old infant after receipt of multiple vaccinations
    Paul McPherson
    Department of Pediatrics, Akron Children s Hospital, Akron, OH, USA
    Pediatr Infect Dis J 24:1010-1. 2005
    ..The report describes hypotonic-hyporesponsive episode, encourages reporting of vaccine-associated adverse events and discusses prognosis and implications for subsequent immunization...
  14. ncbi DTPa-HBV-IPV vaccine for primary vaccination of infants
    Terry Nolan
    Vaccine and Immunisation Research Group, Murdoch Childrens Research Institute and School of Population Health, University of Melbourne, Melbourne, Victoria, Australia
    J Paediatr Child Health 43:587-92. 2007
    ....
  15. ncbi Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule
    Maria Avdicova
    State Institute of Public Health, Hviezdoslavova 19, 97556 Banská Bystrica, Slovakia
    Eur J Pediatr 161:581-7. 2002
    ..Reactogenicity (incidence of solicited local and general symptoms) was similar between the two study groups and no vaccine-related serious adverse events occurred...
  16. ncbi Comparative reactogenicity and parental acceptability of pertussis vaccines administered into the ventrogluteal area and anterolateral thigh in children aged 2, 4, 6 and 18 months
    I F Cook
    Faculty of Medicine and Health Sciences, University of Newcastle, 90 Albert Street, Taree, NSW 2430, Australia
    Vaccine 21:3330-4. 2003
    ..0001) and bruising DTPw study (P<0.0001) and DTPa study (P<0.0004)).Parental acceptability was greater (P<0.0001) in both studies for ventrogluteal injection compared with anterolateral thigh injection...
  17. ncbi Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants
    Terhi Tapiainen
    University Children s Hospital Basel, Division of Pediatrics Infectious Diseases and Vaccines, PO Box 8, 4005 Basel, Switzerland
    Vaccine 23:5106-12. 2005
    ..pertussis, pertactin, is decreased...
  18. ncbi Ongoing control of Haemophilus influenzae type B infections in Canadian children, 2004-2007
    David W Scheifele
    Division of Pediatric Infectious and Immunologic Diseases, University of British Columbia, Vancouver, British Columbia
    Pediatr Infect Dis J 27:755-7. 2008
    ..Surveillance at 12 pediatric centers in 2004-2007 indicates that vaccine failures remain rare and case totals approach an irreducible minimum, with no age shift...
  19. ncbi Alternative diphtheria, tetanus and whooping cough immunization schedule to evoke a Th2 tetanus and a Th1 pertussis immune response
    María Victoria Lavigne
    Instituto de Estudios de la Inmunidad Humoral CONICET UBA, Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, Junín 956 Piso 4, 1113 Buenos Aires, Argentina
    Microbes Infect 6:481-4. 2004
    ..Our findings provide direct evidence that an immunization protocol with an interval of 14 days between DT and Pw primings, followed by DTPa boosters, can induce appropriate immune responses against DTP vaccine antigens...
  20. ncbi High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine
    Peter B McIntyre
    Centre for Immunisation Research, University of Sydney and the Royal Alexandra Hospital for Children, Locked Bag 4001, Westmead, NSW 2145, Australia
    Vaccine 23:380-5. 2004
    ..Adult-formulated dTpa vaccines could replace Td for routine booster vaccination of older individuals...
  21. ncbi Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age
    Rodrigo Vergara
    Escuela de Medicina, Universidad de Valparaiso, Hontaneda 2653, Oficina 318, Valparaiso, Chile
    Eur J Pediatr 164:377-82. 2005
    ..Reactogenicity of dTpa-IPV was comparable to dTpa + IPV, but dTpa-IPV was generally better tolerated than DTPa-IPV...
  22. ncbi A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age
    Lennart Nilsson
    Children s Research Department, Linkoping, Sweden
    Scand J Infect Dis 37:221-9. 2005
    ..The combined DTPa-IPV vaccine could be used to add DTP valences to the IPV vaccine currently given to children in Scandinavia and Italy at 4-6 y of age and reinforce protection against 4 diseases...
  23. ncbi Reduced anti-PRP antibody response to Hib immunisation in preterm (<32 weeks) UK infants who received inactivated polio (eIPV)
    Janet E Berrington
    Department of Neonatology, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK
    Vaccine 25:8206-8. 2007
    ....
  24. ncbi Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT
    Nicole Le Saux
    Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada
    Pediatrics 112:e348. 2003
    ..We hypothesized that the change would result in a decrease in hospitalization rates for seizures and reports of hypotonic-hyporesponsive episodes (HHEs) temporally related to pertussis vaccination...
  25. ncbi Safety and immunogenicity of a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type B combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age
    Tzou Yien Lin
    Division of Pediatric Infectious Diseases, Chang Gung Children s Hospital, Taipei
    Chang Gung Med J 26:315-22. 2003
    ....
  26. ncbi Pertussis vaccine controversies and acellular pertussis vaccine
    Raju C Shah
    S C L Municipal Hospital and Smt N H L Municipal Medical College, Ellis Bridge, Ahmedabad, India
    Indian J Pediatr 70:485-8. 2003
    ..Vaccine efficacy and duration of immunity is comparable with whole cell pertussis vaccine. The adverse events are two thirds less compared to whole cell vaccine...
  27. ncbi Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine
    Roland Sänger
    GlaxoSmithKline GmbH and Co KG, Theresienhoehe 11, 80339 Munich, Germany
    Eur J Pediatr 166:1229-36. 2007
    ..It provides immunity against four diseases in a single injection, with the potential reactogenicity benefit of a reduced-antigen dose...
  28. ncbi Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age
    David W Scheifele
    Vaccine Evaluation Center, BC Children s Hospital, 4500 Oak Street, Vancouver, BC, Canada V6H 3N1
    Vaccine 24:2057-64. 2006
    ..008) and HB responses were reduced (p=0.006) with concurrent dosing, the latter possibly from same thigh injection with DTaP.IPV/Hib. We conclude that PCV7, DTaP.IPV/Hib and HB are compatible with concurrent, separate injections...
  29. ncbi Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose
    Janet E Berrington
    Department of Neonatology, Royal Victoria Infirmary, Newcastle upon Tyne, England
    Pediatrics 117:e717-24. 2006
    ..0 microg/mL) after primary immunization...
  30. ncbi Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Karen R Broder
    Epidemiology and Surveillance Division, National Immunization Program, CDC, USA
    MMWR Recomm Rep 55:1-34. 2006
    ....
  31. ncbi Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines
    Henry Shinefield
    University of California School of Medicine, San Francisco, USA
    Pediatr Infect Dis J 25:287-92. 2006
    ..A study was conducted to assess administration of a combination measles, mumps, rubella and varicella vaccine (MMRV) with other childhood vaccines...
  32. ncbi Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants
    M Knuf
    Pediatric Infectious Disease, Johannes Gutenberg University, Langenbeckstr 1, D 55101 Mainz, Germany
    Vaccine 24:4727-36. 2006
    ....
  33. ncbi Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life
    N Guiso
    Unité de Prévention et Thérapies Moléculaires des Maladies Humaines FRE CNRS 2849, Institut Pasteur, 25 rue du Dr Roux, 75724 Paris Cedex 15, France
    Vaccine 25:1390-7. 2007
    ..At year 6, CMI responses continued to be present and were higher in Pa-vaccinated than Pw-vaccinated subjects. Long-term protection with Pa vaccines can be expected to be at least as good as that provided by efficacious Pw vaccines...
  34. ncbi Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of se
    Jacques Langue
    L Espace Médical, Saint Prest en Jarez, France
    Vaccine 22:1406-14. 2004
    ..The second objective was to evaluate in these 5-6-year-old French children the safety and the immunogenicity of a tetravalent pertussis combined vaccine (DTacP-IPV, Tetravac) given as a second booster...
  35. ncbi Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type B vaccines and evaluation of booster vaccination
    Irmingard Tichmann
    Arztpraxis München, Germany
    Hum Vaccin 2:249-54. 2006
    ..In summary, booster vaccination with Infanrix hexa during the second year of life is immunogenic and well tolerated, offering protection irrespective of the primary combination vaccine used...
  36. ncbi A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants
    Tzou Yien Lin
    Chang Gung Children s Hospital, Taoyuan, Taiwan
    Int J Infect Dis 11:129-36. 2007
    ....
  37. ncbi Safety of DTaP-IPV-HIb-HBV hexavalent vaccine in very premature infants
    Giacomo Faldella
    Istituto di Pediatria Preventiva e Neonatologia, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti 11, 40138 Bologna, Italy
    Vaccine 25:1036-42. 2007
    ....
  38. ncbi Prevention of pertussis across the age spectrum through the use of the combination vaccines PENTACEL and ADACEL
    Scott A Halperin
    Dalhousie University, Canadian Centre for Vaccinology, Departments of Pediatrics and Microbiology and Immunology, IWK Health Centre, 5850 5980 University Avenue, Halifax, Nova Scotia, B3K 6R8, Canada
    Expert Opin Biol Ther 6:807-21. 2006
    ..These products have been demonstrated to be safe, immunogenic and effective for the control of pertussis and the other included diseases...
  39. pmc Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components
    Ron Dagan
    Pediatric Infectious Disease Unit, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University, Beer Sheva 84101, Israel
    Infect Immun 72:5383-91. 2004
    ..With the increasing use of multiple aP-containing vaccines in infancy, novel approaches to adjuvants and carrier protein technology are likely to be required...
  40. ncbi One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine
    Tzou Yien Lin
    Department of Pediatrics, Chang Gung Children s Hospital, Chang Gung Memorial Hospital, Chang Gung University Medicine, Taoyuan, Taipei, Taiwan
    Int J Infect Dis 11:488-95. 2007
    ....
  41. ncbi [Assessment of postvaccinal response in children past pertussis]
    Krystyna Grzybowska
    Katedry Pediatrii i Immunologii Wieku Rozwojowego Uniwersytetu Medycznego w Lodzi
    Wiad Lek 59:819-22. 2006
    ..The study estimates parameters of postvaccinal response to immunization with selected vaccines in children post whooping cough...
  42. ncbi Comparative trial to assess the reactogenicity of the diphtheria-tetanus-acellular pertussis (DTPa) vaccine plus Haemophilus influenzae type B (Hib) conjugate vaccine and that of the diphtheria-tetanus-whole cell pertussis (DTPw) vaccine plus Hib conjugat
    Francisco Calbo
    Departamento de Medicina Preventiva, Hospital Carlos Haya, Malaga, Spain
    Med Clin (Barc) 118:1-4. 2002
    ....
  43. ncbi A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial
    David W Scheifele
    Canadian Association for Immunization Research and Evaluation CAIRE and the Vaccine Evaluation Center, BC Children s Hospital and the University of British Columbia, Vancouver, British Columbia, Canada
    Pediatr Infect Dis J 24:1059-66. 2005
    ..Large injection site reactions commonly follow booster doses of diphtheria-tetanus-acellular pertussis (DTaP) vaccines at 4-6 years of age. A vaccine with lower diphtheria and pertussis dosage (Tdap) might be better tolerated for this dose...
  44. ncbi Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review
    J M Jacquet
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Vaccine 24:2440-8. 2006
    ..5% of DTPw-primed children. Large swelling involving the entire upper arm (extending to involve the elbow joint) was reported for up to 1.2% of DTPa-primed subjects, which is consistent with literature reports for other DTPa vaccines...
  45. ncbi Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants
    S H Yeh
    UCLA Center for Vaccine Research, Research and Education Institute, Torrance, CA, USA
    Pediatr Infect Dis J 20:973-80. 2001
    ....
  46. ncbi Immunogenicity of a combined DTPa-HB vaccine co-administered with Haemophilus influenzae type B conjugate vaccine (PRP-T) for primary and booster vaccinations
    Humberto Bracco Neto
    Department of Pediatrics, Federal University of Sao Paulo, Rua Correa de Lemos 780, Sao Paulo, SP, Brazil
    Braz J Infect Dis 9:363-73. 2005
    ..To evaluate the immunogenicity of a combined DTPa-HB vaccine co-administered with Haemophilus influenzae type b conjugate vaccine (PRP-T) in Brazilian infants...
  47. ncbi Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study
    Elinor Reynolds
    National Institute for Biological Standards and Control, Division of Bacteriology, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK
    Vaccine 24:3248-57. 2006
    ..Protection against aerosol challenge with virulent Bordetella pertussis was related to the magnitude of the antibody and CMI responses in the mouse model. As in the human subjects, the responses remained skewed towards Th1 type...
  48. ncbi Early responses to nonconjugated polyribosylribitol phosphate challenge as evidence of immune memory after combined diphtheria-tetanus-pertussis-polio-Haemophilus influenzae type b primary vaccination
    R Dagan
    Soroka University Medical Center, and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
    Pediatr Infect Dis J 20:587-92. 2001
    ..The ability of primed infants to mount a rapid response is an important observation given the high risk of Hib infection at this critical age...
  49. ncbi How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?
    Scott A Halperin
    Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada
    Pediatr Infect Dis J 25:195-200. 2006
    ....
  50. ncbi Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules
    Michael E Pichichero
    Microbiology and Immunology, Pediatrics and Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 672, Rochester, NY 14642, USA
    Clin Pediatr (Phila) 45:613-20. 2006
    ..Seroprotective levels and antibody concentrations were comparable regardless of prior DTaP/DTwP vaccine history. A sixth sequential dose of Tdap after 5 doses of DTaP appears safe and immunogenic...
  51. ncbi Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States
    Vitali Pool
    Vaccine Safety and Development Activity, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Pediatrics 110:e71. 2002
    ....
  52. ncbi Impact of a decline in Colorado Medicaid managed care enrollment on access and quality of preventive primary care services
    Stephen Berman
    Department of Pediatrics, University of Colorado School of Medicine, Denver, Colorado, USA
    Pediatrics 116:1474-9. 2005
    ..5% to 25.3%. This shift of children from HMO managed care to the UFFS program provided a natural experiment to assess the impact of not having an assigned PCP on pediatric primary care services...
  53. ncbi Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines
    M B Rennels
    University of Maryland School of Medicine, Baltimore, Maryland, USA
    Pediatrics 105:e12. 2000
    ..However, local reactions increase in rate and severity with each successive DTaP dose, and swelling of the entire injected limb has been reported after booster doses...
  54. ncbi [Seroconversion after vaccination against pertussis, Haemophilus influenzae type b and poliomyelitis in preterm infants]
    Janusz Piotr Sikora
    Klinika Propedeutyki Pediatrii IP Uniwersytetu Medycznego w Łodzi
    Przegl Lek 60:699-703. 2003
    ....
  55. pmc Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis
    James D Cherry
    Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1752, USA
    Clin Vaccine Immunol 17:741-7. 2010
    ..Our findings lend support to the idea that DTaP vaccines should contain multiple antigens...
  56. ncbi Expression and purification of a trivalent pertussis toxin-diphtheria toxin-tetanus toxin fusion protein in Escherichia coli
    Mahdi Aminian
    Department of Microbiology and Immunology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada B3H 3J5
    Protein Expr Purif 51:170-8. 2007
    ..Antisera generated against the purified PDT protein recognized the native toxins indicating that some, if not all, of the native epitopes were conserved...
  57. ncbi Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age
    R Dagan
    Soroka University Medical Center and the Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
    Vaccine 17:2620-7. 1999
    ..This can be conveniently accomplished by combining acellular pertussis antigens with diphtheria and tetanus toxoids. However the optimal dosage for the booster injection has not yet been determined...
  58. ncbi Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children
    M E Pichichero
    Department of Microbiology, University of Rochester School of Medicine, Rochester, New York, USA
    Pediatrics 105:e11. 2000
    ....
  59. ncbi Safety and immunogenicity of a diphtheria, tetanus, acellular pertussis and Haemophilus influenzae Type b combination vaccine compared with separate administration of licensed equivalent vaccines in Chinese infants and toddlers for primary and booster imm
    Guifan Li
    Beijing Minhai Biotechnology Co Ltd, Beijing, China
    Vaccine 28:4215-23. 2010
    ..There could be a bright future for the DTaP/Hib vaccine to be widely used in the universal vaccination of Chinese children...
  60. ncbi DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa): A Review of its Use as Primary and Booster Vaccination
    Sohita Dhillon
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:1021-58. 2010
    ....
  61. ncbi Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines
    A E Tozzi
    Laboratory of Epidemiology and Biostatistics, Istituto Superiore di Sanita, Rome, Italy
    Pediatrics 107:E25. 2001
    ....
  62. ncbi Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy
    Mark J Abzug
    School of Medicine, University of Colorado and Children s Hospital, Denver, Colorado, USA
    Pediatrics 120:e1190-202. 2007
    ..Our goal was to evaluate the immunogenicity and safety of pertussis booster vaccination in children infected with HIV on highly active antiretroviral therapy (HAART)...
  63. ncbi Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US
    Greg L Plosker
    Wolters Kluwer Health Adis, Mairangi Bay, North Shore, Auckland, New Zealand
    BioDrugs 23:253-67. 2009
    ..Therefore, as a single-dose booster vaccine, Boostrix provides a useful option to reduce pertussis morbidity and maintain the standard of care for tetanus and diphtheria protection in individuals aged 10-64 years...
  64. ncbi Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines
    M H Slack
    Department of Neonatal Medicine, Princess Anne Hospital, Southampton, United Kingdom
    J Infect Dis 184:1617-20. 2001
    ..Hib IgG was associated with age at third immunization (P<.001). When combined with the DTaP vaccine used in this study, the Hib GMC of premature infants was extremely low. The SBA GMT to MCC was similar to that of term infants...
  65. ncbi Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine
    J Southern
    Immunisation Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
    Vaccine 24:215-9. 2006
    ..These results suggest that a reduced number of doses of MCC-TT would be adequate in infancy if given concomitantly with an acellular pertussis-containing vaccine...
  66. ncbi Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer
    Elisabet Bergfors
    Department of Primary Health Care, Goteborg University, Box 454, S 40530 Göteborg, Sweden
    Vaccine 22:64-9. 2003
    ..g. vaccines and antiperspirants). The reason for the high incidence of itching nodules after SSI vaccines is unknown and should be further investigated...
  67. ncbi Routine immunizations and adverse events in infants with single-ventricle physiology
    Brian McAlvin
    Sibley Heart Center Cardiology, Children s Healthcare of Atlanta, Atlanta, Georgia, USA
    Ann Thorac Surg 84:1316-9. 2007
    ..In an effort to decrease the risk of sudden death, some centers have advocated that routine immunizations be deferred in this population. However, it is not known if an association exists between immunizations and adverse events...
  68. ncbi Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination
    P Habermehl
    Pediatric Immunology and Infectious Diseases, Johannes Gutenberg University, Mainz, Germany
    Vaccine 17:669-74. 1999
    ....
  69. pmc A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines
    Cristina Giambi
    Communicable Disease Epidemiology Unit, National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    BMC Infect Dis 8:100. 2008
    ..The objectives of this study were to evaluate the persistence of antibodies to anti-HBs, in children in the third year of life, and to investigate the response to a booster dose of hepatitis B vaccine...
  70. ncbi Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands
    Silke David
    RIVM, Centre for Infectious Disease Control Netherlands, Preparedness and Response Unit, P O Box 1, 3720 BA Bilthoven, The Netherlands
    Vaccine 26:5883-7. 2008
    ....
  71. ncbi Fragmentation of immunization history among providers and parents of children in selected underserved areas
    Hussain Yusuf
    Immunization Services Division, National Immunization Program, Centers for Disease Control and Prevention Yusuf, Adams, Rodewald, LU, Rosenthal, Santoli, Atlanta, Georgia 30333, USA
    Am J Prev Med 23:106-12. 2002
    ..We assessed fragmentation of children's immunization history among providers and parents of children aged 12 to 35 months in four selected underserved areas...
  72. ncbi Mercury in vaccines from the Australian childhood immunization program schedule
    David W Austin
    Faculty of Life and Social Sciences, Swinburne University of Technology, Melbourne, Australia
    J Toxicol Environ Health A 73:637-40. 2010
    ....
  73. ncbi Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children
    N N Tran Minh
    National Public Health Institute, Department in Turku, Finland
    Vaccine 16:1604-10. 1998
    ..The results show that booster immunization with an acellular pertussis vaccine with reduced concentrations of antigens induces both antibody and CMI responses and support further studies of this pertussis vaccine in school children...
  74. ncbi Parenteral immunization of mice with a genetically inactivated pertussis toxin DNA vaccine induces cell-mediated immunity and protection
    Scott R Fry
    Department of Biological and Physical Sciences, University of Southern Queensland, Toowoomba 4350, Queensland, Australia
    J Med Microbiol 57:28-35. 2008
    ..DTaP-immunized mice cleared the aerosol challenge more efficiently than DNA-immunized mice, with no detectable pathogen after day 7 post-challenge...
  75. ncbi Oral glucose as an analgesic to reduce infant distress following immunization at the age of 3, 5 and 12 months
    Margit Thyr
    Department of Children s Health, Bollnäs Health Centre, Bollnäs, Sweden
    Acta Paediatr 96:233-6. 2007
    ..To evaluate oral glucose as an analgesic to reduce infant distress after immunization during the first year of life and to investigate if these effects change during this period...
  76. ncbi Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine
    Fong Seng Lim
    National Health Care Group Polyclinics, Choa Chu Kang, Singapore
    Ann Acad Med Singapore 36:801-6. 2007
    ..We investigated whether a combined hexavalent vaccine, DTPa-HBV-IPV/Hib, could replace the separate administration of DTPa-IPV/Hib and HBV for the final vaccination at 5 months of age (Trial DTPa-HBV-IPV-075)...
  77. ncbi Adverse reactions to immunization with newer vaccines in the very preterm infant
    Vanessa J Ellison
    Division of Newborn Services, The Royal Women s Hospital, Victoria, Australia
    J Paediatr Child Health 41:441-3. 2005
    ..To study the frequency and types of adverse reactions to currently available vaccines in very preterm infants...
  78. ncbi Low hepatitis B immunogenicity of a hexavalent vaccine widely used in Germany: results of the German Health Survey for Children and Adolescents, 2003-2006
    P Jorgensen
    Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
    Epidemiol Infect 138:1621-9. 2010
    ..Further studies are warranted to assess whether Hexavac vaccinees should be re-vaccinated or receive a booster vaccination before these birth cohorts reach adolescence...
  79. ncbi Immunogenicity and reactogenicity of DTPa-HBV-IPV/Hib vaccine as primary and booster vaccination in low-birth-weight premature infants
    Liliana Vazquez
    Fundación Centro de Estudios Infectológicos, Buenos Aires, Argentina
    Acta Paediatr 97:1243-9. 2008
    ..To assess suitability of a combined DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) for immunization of low-birth-weight (<2.0 kg) preterm infants, with particular focus on the hepatitis B response...
  80. ncbi Validation of a new ELISA method for in vitro potency assay of hepatitis B-containing vaccines
    D Giffroy
    GlaxoSmithKline Biologicals, 89 Rue de l Institut, 1880 Rixensart, Belgium
    Pharmeuropa Bio 2006:7-14. 2006
    ..Further validation studies should focus on the use of this ELISA with vaccines from other manufacturers...
  81. ncbi Kinetics of asthma- and allergy-associated immune response gene expression in peripheral blood mononuclear cells from vaccinated infants after in vitro re-stimulation with vaccine antigen
    Anne I Lahdenperä
    Division of Paediatrics, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, 58185 Linkoping, Sweden
    Vaccine 26:1725-30. 2008
    ..At 12h after in vitro re-stimulation of the PBMC with pertussis toxin (PT) antigen, 14 immune response pathways, 33 allergy-related and 66 asthma-related genes were found activated...
  82. ncbi Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine
    C Boursaux-Eude
    Laboratoire des Bordetella, Institut Pasteur, Paris, France
    Vaccine 17:2651-60. 1999
    ..pertussis variants...
  83. ncbi [The effectiveness and safety of vaccine against meningococci group C conjugated with tetanus toxoid co-administrated with different vaccines--literature review]
    Teresa Jackowska
    Klinika Pediatrii, Centrum Medyczne Kształcenia Podyplomowego w Warszawie
    Przegl Epidemiol 64:99-103. 2010
    ..Review of articles on efficacy and safety of co-administration of Neisseria meningitidis serogroup C -tetanus toxoid conjugate vaccine (NeisVac-C) with other vaccines...
  84. ncbi Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years
    Wayde M Weston
    GlaxoSmithKline Biologicals, 2301 Renaissance Boulevard, RN0220, King of Prussia, PA 19406, USA
    Expert Rev Vaccines 7:1309-20. 2008
    ..Strategies such as the use of combined vaccines can help to maintain high levels of coverage against diphtheria, tetanus, pertussis and poliomyelitis diseases...
  85. ncbi Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT
    Helen Findlow
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, PO Box 209, Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester, M13 9WZ, UK
    Adv Ther 30:431-58. 2013
    ..Studies in young infants from 2 months of age have now commenced but immunisation with a single dose of ACWY-TT from 12 months of age is a safe and immunogenic option in the prevention of meningococcal disease...
  86. ncbi Characterization of pertussis toxoid by two-dimensional liquid chromatography-tandem mass spectrometry
    Manorama Tummala
    Baxter Healthcare, Technology Resources, Round Lake, IL 60073, USA
    Anal Biochem 401:295-302. 2010
    ..Evidence of histidine and tyrosine oxidation was also observed. In addition, a large percentage of asparagine was found hydrolyzed to aspartic acid. These findings corrrelate well with the reduction of PT toxicity by peroxide treatment...
  87. ncbi Absence of an increase in cardiorespiratory events after diphtheria-tetanus-acellular pertussis immunization in preterm infants: a randomized, multicenter study
    Tracy Carbone
    Center for Pediatric Sleep Disorders, Valley Hospital, 505 Goffle Rd, Ridgewood, NJ 07450, USA
    Pediatrics 121:e1085-90. 2008
    ....
  88. ncbi Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines
    Jacek Wysocki
    University School of Medical Sciences and Regional Medical Center for Mother and Child, Poznan, Poland
    Pediatr Infect Dis J 28:S77-88. 2009
    ....
  89. ncbi Using computer decision support to increase maternal postpartum tetanus, diphtheria, and acellular pertussis vaccination
    William E Trick
    Collaborative Research Unit, Stroger Hospital of Cook County, Chicago, Illinois, USA
    Obstet Gynecol 116:51-7. 2010
    ....
  90. ncbi Review of a new fully liquid, hexavalent vaccine: Hexaxim
    Marta C Nunes
    University of Witwatersrand, Department of Science and Technology Vaccine Preventable Diseases Unit, Johannesburg, South Africa
    Expert Opin Biol Ther 13:575-93. 2013
    ..A new, fully liquid formulation hexavalent vaccine ( Hexaxim ) has been developed and is currently undergoing licensure for use in childhood immunization programs...
  91. ncbi Effects of simultaneous immunization of Haemophilus influenzae type b conjugate vaccine and diphtheria-tetanus-acellular pertussis vaccine on anti-tetanus potencies in mice, guinea pigs, and rats
    Tadashi Fukuda
    Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo 208 0011, Japan
    Jpn J Infect Dis 66:41-5. 2013
    ..These results provide useful information regarding the use of HibT-containing multivalent vaccines in childhood immunization...
  92. ncbi Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age
    Lennart Gustafsson
    Swedish Institute for Infectious Disease Control, SE 171 82 Solna, Sweden
    Pediatrics 118:978-84. 2006
    ..The purpose of this work was to evaluate the long-term effectiveness of vaccination with acellular pertussis vaccines at 3, 5, and 12 months of age...
  93. ncbi Safety and immunogenicity of a pentavalent combination vaccine (diphtheria, tetanus, acellular pertussis, polio, and haemophilus influenzae type B conjugate) when administered as a fourth dose at 15 to 18 months of age
    D W Scheifele
    Vaccine Evaluation Center, British Columbia s Children s Hospital, Vancouver, British Columbia, Canada
    Hum Vaccin 1:180-6. 2005
    ..The fourth dose was well tolerated in all age groups. Toddlers at 15, 16, 17 or 18 months of age are equally suitable recipients for booster immunization with the DTaP-IPV//PRP-T vaccine...
  94. ncbi Safety of a fifth dose of diphtheria and tetanus toxoid and acellular pertussis vaccine in children experiencing extensive, local reactions to the fourth dose
    Margaret B Rennels
    Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    Pediatr Infect Dis J 27:464-5. 2008
    ..Of 20 children with extensive local reactions after dose 4, only 4 experienced entire upper arm swelling and 7 had swelling >5 cm after dose 5. These reactions were well tolerated and support revaccination...
  95. ncbi Lot-to-lot consistency of a combined hexavalent diptheria-tetanus-acellular-pertussis, hepatitis B, Inactivated polio and haemophilus B conjugate vaccine, administered to healthy chilean infants at two, four and six months of age
    Rosanna Lagos
    Centro para Vacunas en Desarollo, Santiago, Chile
    Hum Vaccin 1:112-7. 2005
    ..To assess the safety, immunogenicity and lot consistency of a liquid hexavalent combined vaccine (DTaP-IPV-PRP approximately T-HBs, HEXAVAC) (Sanofi-Pasteur MSD, France) administered to infants at two, four and six months of age...
  96. ncbi The preteen visit: an opportunity for prevention
    Doug Campos-Outcalt
    Department of Family and Community Medicine, University of Arizona College of Medicine, 4001 North Third Street 415, Phoenix, AZ 85012, USA
    J Fam Pract 55:1054-6. 2006
    ..In addition, 2 doses of varicella vaccine are now recommended before age 5 years; both boys and girls at age 11 or 12 who have received only 1 dose should be given a second...
  97. ncbi Update: Vaccines for women, adolescence through adulthood
    Iyabode Akinsanya-Beysolow
    Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Womens Health (Larchmt) 18:1101-8. 2009
    ..Obstetrician-gynecologists can help reduce some of these obstacles by availing themselves of existing vaccination resources...
  98. ncbi Pertussis immunization in a high-risk postpartum population
    C Mary Healy
    Center for Vaccine Awareness and Research, Texas Children s Hospital, Houston, TX, United States
    Vaccine 27:5599-602. 2009
    ..Barriers to postpartum immunization include inaccurate immunization history and the need for ongoing targeted education...
  99. ncbi Effects of a minimum interval immunization schedule for diphtheria and tetanus toxoids and acellular pertussis vaccination during a pertussis outbreak
    Daniel Bronson-Lowe
    Arizona Department of Health Services, Phoenix, AZ 85007, USA
    Arch Pediatr Adolesc Med 163:417-21. 2009
    ....
  100. ncbi An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adol
    Timo Vesikari
    Vaccine Research Centre, University of Tampere Medical School, Tampere, Finland
    Pediatr Infect Dis J 29:314-8. 2010
    ..In this study, we evaluated the immunogenicity and safety of GARDASIL administered concomitantly with REPEVAX (diphtheria, tetanus, acellular pertussis, and poliomyelitis vaccine)...
  101. ncbi Potential impact of acceleration of the pertussis vaccine primary series for infants
    Myrick C Shinall
    School of Medicine, Divinity School, Vanderbilt University, Nashville, Tennessee, USA
    Pediatrics 122:1021-6. 2008
    ....

Research Grants8

  1. Neonatal Immunization with Acellular Pertussis Vaccines
    Natasha Halasa; Fiscal Year: 2007
    ....
  2. Using MEPS Data to Inform Public-Plan Consumerism
    Matthew Davis; Fiscal Year: 2007
    ..Findings will have immediate relevance for implementation of the HOA projects and other consumerism efforts. [unreadable] [unreadable] [unreadable]..
  3. Strategies for Group A Streptococcal Prevention
    Grace Lee; Fiscal Year: 2008
    ..During her K Award, she hopes to establish herself as a multidisciplinary researcher in the fields of decision sciences, infectious disease modeling, and health policy. [unreadable] [unreadable]..
  4. Communication, Perspectives, & Child Asthma Disparities
    Tracy Lieu; Fiscal Year: 2005
    ..This information is critical to the design of effective, culturally tailored interventions to eliminate disparities in health care for childhood asthma and other chronic diseases. ..
  5. Decision Analysis of Otitis Media Vaccination Strategies
    Tracy Lieu; Fiscal Year: 2005
    ..The decision analytic model will yield information toward the optimal choices for current scientific inquiry, and will also provide a foundation for updated analyses as otitis media vaccines are further developed and tested. ..
  6. Family Decision Making and Burden Under High-Deductible Health Plans
    Tracy Lieu; Fiscal Year: 2008
    ..They will also create essential building blocks for future studies of how cost containment approaches affect the health of children, parents, and families. [unreadable] [unreadable] [unreadable]..
  7. Enhancing Prevention for Children in Diverse Populations
    Tracy Lieu; Fiscal Year: 2008
    ..Support from this K24 award will come at a critical time for Dr. Lieu and for the junior faculty in her new Center. [unreadable] [unreadable]..
  8. The Population-Based Effectiveness in Asthma and Lung Diseases (PEAL) Network
    Tracy A Lieu; Fiscal Year: 2010
    ..This project is innovative in that we will link claims, electronic medical record, patient, and provider data, and will build new linkages with a Medicaid plan to include vulnerable groups who are disproportionately burdened by asthma. ..